EAU 2017: Does nadir testosterone at the end of long term androgen deprivation therapy predict outcomes in high risk prostate cancer? Data from a phase III trial

London, England. Dr. Nabid and colleagues presented their study this morning at the EAU 2017’s advanced prostate cancer poster session, assessing the impact of nadir testosterone on clinical outcomes after long-term androgen deprivation therapy (ADT) and radiotherapy (RT) for high risk prostate cancer. With emerging literature highlighting additional risks of ADT, including depression, cognitive decline, etc., this study is timely in assessing duration of ADT with regards to castrate testosterone levels and subsequent clinical outcomes.